000177098 001__ 177098
000177098 005__ 20240326155615.0
000177098 0247_ $$2doi$$a10.1186/s12885-021-08845-x
000177098 0247_ $$2pmid$$apmid:34663263
000177098 0247_ $$2altmetric$$aaltmetric:115436835
000177098 037__ $$aDKFZ-2021-02301
000177098 041__ $$aEnglish
000177098 082__ $$a610
000177098 1001_ $$0P:(DE-He78)98a8f1a22ffc460364a8a34499118103$$aZheng, Guoqiao$$b0$$eFirst author
000177098 245__ $$aTypes of second primary cancer influence overall survival in cutaneous melanoma.
000177098 260__ $$aHeidelberg$$bSpringer$$c2021
000177098 3367_ $$2DRIVER$$aarticle
000177098 3367_ $$2DataCite$$aOutput Types/Journal article
000177098 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711464906_22852
000177098 3367_ $$2BibTeX$$aARTICLE
000177098 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177098 3367_ $$00$$2EndNote$$aJournal Article
000177098 520__ $$aFavorable survival in malignant cutaneous melanoma (melanoma) has increased the likelihood of second primary cancer (SPC). We assess the influence of patient characteristics at diagnosis of first melanoma and the type of SPC (second melanoma and other SPC) on overall survival.We used the Swedish Cancer Registry data to assess overall survival in melanoma for the period 1990 to 2015. Kaplan-Meier curves were plotted and hazard ratios (HRs) were estimated with Cox regression models by considering SPC diagnosis as a time-dependent variable.A total of 46,726 patients were diagnosed with melanoma, and 15.3% of them developed SPC, among which, two thirds were other SPCs. Second melanomas were diagnosed early (31% during the first year) compared to non-melanoma SPCs (9.5%). Survival for women with second melanoma or other SPC (56 and 21% alive after 25 years of follow-up, respectively) exceeded the male rates (21 and 10%, respectively) but all these figures were lower than for females (60% alive) or males (48%) without SPC. Time dependent analysis showed vastly increased HRs for cancer types that are fatal also as first cancers, but SPC-specific HRs remained relatively uniform, irrespective of SPC diagnosed soon or late after first melanoma. In early-onset melanoma, SPC diagnosis after 10 years may not negatively influence overall survival.As the overall survival of patients with many types of SPCs is unfavorable, advice about health lifestyle should benefit smoking patients and early detection methods may be recommended for SPCs of the breast, prostate and colorectum.
000177098 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000177098 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177098 650_7 $$2Other$$aIndependent primary
000177098 650_7 $$2Other$$aOverall survival
000177098 650_7 $$2Other$$aPrognosis
000177098 650_7 $$2Other$$aSecond melanoma
000177098 650_7 $$2Other$$aTime-dependent analysis
000177098 7001_ $$0P:(DE-He78)9918be87133a5ff93034e03087506c3c$$aChattopadhyay, Subhayan$$b1
000177098 7001_ $$aSundquist, Kristina$$b2
000177098 7001_ $$aSundquist, Jan$$b3
000177098 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b4
000177098 7001_ $$aHemminki, Akseli$$b5
000177098 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b6$$eLast author$$udkfz
000177098 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-021-08845-x$$gVol. 21, no. 1, p. 1123$$n1$$p1123$$tBMC cancer$$v21$$x1471-2407$$y2021
000177098 909CO $$ooai:inrepo02.dkfz.de:177098$$pVDB
000177098 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)98a8f1a22ffc460364a8a34499118103$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000177098 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9918be87133a5ff93034e03087506c3c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000177098 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000177098 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000177098 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000177098 9141_ $$y2021
000177098 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2019$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2021-05-04
000177098 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000177098 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000177098 9202_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000177098 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000177098 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000177098 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000177098 9200_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000177098 980__ $$ajournal
000177098 980__ $$aVDB
000177098 980__ $$aI:(DE-He78)C050-20160331
000177098 980__ $$aI:(DE-He78)B062-20160331
000177098 980__ $$aI:(DE-He78)HD01-20160331
000177098 980__ $$aUNRESTRICTED